This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Edwards Lifesciences (EW) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Evaluate Edwards Lifesciences' (EW) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Edwards Lifesciences (EW) Q2 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 16.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Can These 4 MedTech Stocks Hit Targets This Earnings Season?
by Urmimala Biswas
Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
by Zacks Equity Research
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Universal Health (UHS) Gains 28% in a Year: What Lies Ahead?
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on the back of growing patient volumes, acquisitions and a commendable financial position.
HOLX vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
by Zacks Equity Research
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Edward Lifesciences (EW) for Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences (EW), led by the strong performance of its SAPIEN 3 Ultra RESILIA platform and strong solvency.
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
by Zacks Equity Research
Salesforce, BP, The Southern, PayPal and Edwards Lifesciences are included in this Analyst Blog.
Top Analyst Reports for Salesforce, BP & Southern Co.
by Mark Vickery
Toda's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), BP p.l.c. (BP) and The Southern Company (SO).
ALC vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. EW: Which Stock Is the Better Value Option?
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.